Filing Details
- Accession Number:
- 0001209191-21-026670
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-14 16:59:44
- Reporting Period:
- 2021-04-12
- Accepted Time:
- 2021-04-14 16:59:44
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1651944 | Dermtech Inc. | DMTK | Services-Medical Laboratories (8071) | 842870849 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1787176 | John Dobak | C/O Dermtech, Inc. 11099 N. Torrey Pines Road, Suite 100 La Jolla CA 92037 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-04-12 | 14,343 | $45.94 | 550,773 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-04-12 | 9,736 | $46.79 | 541,037 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-04-12 | 921 | $47.90 | 540,116 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021.
- This transaction was executed in multiple trades at prices ranging from $45.44 to $46.42, inclusive. The reported price reflects the weighted-average sale price.
- This transaction was executed in multiple trades at prices ranging from $46.53 to $47.51, inclusive. The reported price reflects the weighted-average sale price.
- This transaction was executed in multiple trades at prices ranging from $47.55 to $48.00, inclusive. The reported price reflects the weighted-average sale price.
- The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (4) of this Form 4.